In order to expand the repertoire of antigens that can be targeted by this approach, therefore expanding the number of patients and tumor types that can be treated, we developed a TCR-expressing vector targeting a member of the synovial sarcoma X breakpoint family, SSX2. This evidence concerns the gene SSX2 and neoplasm.